Cloudbreak Pharma Inc
02592
Company Profile
Business description
Cloudbreak Pharma Inc is an innovation-driven clinical-stage ophthalmology biotechnology company dedicated to the development of novel and differentiated treatments. The company’s focus is on Meibomian Gland Dysfunction Associated Dry Eye Disease, Pterygium, Pinguecula, Glaucoma Filtration Surgery, Wet Age-Related Macular Degeneration, and Myopia Progression. Its drugs in pipeline include CBT-001, CBT-004, CBT-006, CBT-007, CBT-009, and CBT-011.
Contact
8921 Research Drive
IrvineCA92618
USASector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
Stocks News & Analysis
stocks
After Earnings, is Alphabet stock a buy, a sell, or fairly valued?
With a diverse portfolio of innovative technology and integrated media platforms, here’s what we think of Alphabet’s stock.
stocks
Moated ASX share crashes amid weak trading update
Bapcor signalled lower underlying profits for fiscal 2025, while an audit cast doubt on the firm’s past earnings.
stocks
A collection of our best stock opportunities
Our latest articles about where we see opportunities in the market.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,017.90 | 51.20 | 0.57% |
| CAC 40 | 7,857.36 | 56.48 | 0.72% |
| DAX 40 | 24,217.37 | 247.01 | 1.03% |
| Dow JONES (US) | 44,632.99 | 204.57 | -0.46% |
| FTSE 100 | 9,136.32 | 54.88 | 0.60% |
| HKSE | 25,318.77 | 205.68 | -0.81% |
| NASDAQ | 21,098.29 | 80.29 | -0.38% |
| Nikkei 225 | 40,610.31 | 64.24 | -0.16% |
| NZX 50 Index | 12,855.97 | 80.44 | -0.62% |
| S&P 500 | 6,370.86 | 18.91 | -0.30% |
| S&P/ASX 200 | 8,759.00 | 54.40 | 0.62% |
| SSE Composite Index | 3,627.70 | 17.99 | 0.50% |